UCB has announced a new partnership with the UK's Medical Research Council (MRC) that focuses on antibody discovery.
The collaboration aims to support academic researchers seeking to develop antibody-based therapeutics, with the MRC providing funding for up to five projects per year over the next three years.
“UCB has announced a new partnership with the Medical Research Council to support academic researchers seeking to develop antibody-based therapeutics.“
Selected projects will be given access to UCB's antibody platform, based in Slough, in order to generate novel antibodies that can be tested in models of disease. This process will be assisted by UCB's high-throughput antibody discovery technology, which automates key processes to expand capacity, increase speed and improve consistency.
The call for submissions came on August 2nd and will close on September 27th, with projects expected to start during the second quarter of 2018.
A company statement said: "This joint initiative with the MRC is a world-leading collaboration between academia and industry with the aim of enhancing the pace of new drug discovery and improving patient outcomes."
This collaboration complements UCB's existing Antibody Technology Platform Access Programme, which has already resulted in alliances with institutions including the University of Oxford, University College London and Weill Cornell Medical College.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical